Merck
770 West Point Pike
PO Box 250
West Point, PA 19486-0250

August 15, 2016

PRODUCT DISCONTINUATION NOTICE: GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant]

Dear Health Care Professional,

This letter is to inform you that Merck will no longer sell GARDASIL in the US effective on or before October 31, 2016. GARDASIL® 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) is available and is not impacted by this action.

This decision is not related to any product safety or manufacturing issues with GARDASIL, and only affects customers in the United States.

On or before October 31, 2016, GARDASIL will no longer be available for purchase directly from Merck. We do not have a specific date of when our supply of GARDASIL will be depleted. Wholesalers and physician distributors may have inventory remaining, which may continue to be purchased until their supply is depleted. All remaining doses of GARDASIL distributed by Merck in the United States will have an expiry date in May 2017.

GARDASIL will remain on all private sector contracts and pricing programs, and will not be removed from these contracts and pricing programs until the expiry date of the final doses. Until GARDASIL is removed from Merck's private sector contracts and pricing programs, the terms and conditions of your contracts and programs are not affected by this change, including our return policy for customers that buy directly from Merck.

We thank you for your commitment to public health and to Merck Vaccines.

If you have any questions, please contact your Merck account representative or call the Merck Vaccine Customer Center at 877-VAX-MERCK (877-829-6372), Monday through Friday, 8:00 AM to 7:00 PM ET.

Sincerely,

Eric Rothstein
US Marketing Leader, Adolescent Vaccines
Merck

Copyright © 2016 Merck Sharp & Dohme Corp., a subsidiary of **Merck & Co., Inc**. All rights reserved.
VACC-1188063-0000 07/16